Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Embla Medical hf's average EBITDA Per Share Growth Rate was 2.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 12.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 14.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 7.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Embla Medical hf was 41.80% per year. The lowest was -5.60% per year. And the median was 12.70% per year.
Embla Medical hf (OTCPK:OSSFF) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Embla Medical hf 5-Year EBITDA Growth Rate Related Terms
OSSFF vs ABT, SYK, MDT: 5-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Embla Medical hf's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's 5-Year EBITDA Growth Rate falls into.
Embla Medical hf 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 14.70% mean?
Embla Medical hf (OSSFF) has a 5-Year EBITDA Growth Rate of 14.70% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Embla Medical hf and its competitors.
Is Embla Medical hf's 5-Year EBITDA Growth Rate too high?
Embla Medical hf's current 5-Year EBITDA Growth Rate is 14.70%. Overall, Embla Medical hf has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's 5-Year EBITDA Growth Rate compare to ABT and SYK?
Embla Medical hf's 5-Year EBITDA Growth Rate of 14.70% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Embla Medical hf and its competitors. Embla Medical hf's current 5-Year EBITDA Growth Rate is 14.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current 5-Year EBITDA Growth Rate of 14.70%. The stock's GF Value™ is $5.43, compared to a current price of $4.15 — trading 23.6% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 14.70%. Embla Medical hf's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current 5-Year EBITDA Growth Rate is 14.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 23.6% below its estimated GF Value™ of $5.43.
Key valuation signals for OSSFF:
5-Year EBITDA Growth Rate: 14.70%
GF Value™: $5.43 vs. price of $4.15 (23.6% below fair value)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
91GF Score
Get the complete analysis for OSSFF
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
